NK-like activation markers (e.g., NKG2D, CD16) assess solid tumor cytotoxicity, while baseline IL-6, CAR signal strength, and combined analyses can anticipate cytokine release syndrome (CRS). The gene discussed is KLRK1; the disease is congenital rubella syndrome.